"These findings help differentiate the placenta as a source of...

"These findings help differentiate the placenta as a source of cells for immunotherapy and demonstrate the valuable potential of our placental platform for allogeneic CAR-T products," said Dr. Robert Hariri, founder, Chairman and CEO of Celularity. "As the field of cellular immunotherapy moves towards delivering ‘one-size-fits-all’ allogeneic products, the stemness advantages inherent in our platform have the potential to translate into improved persistence and durable activity with an enhanced safety profile, offering promising prospects for developing more effective CAR-T therapies in the future. Moreover, we believe that our placental platform offers a level of scalability and consistency in manufacturing which can significantly impact the economics of delivering these therapies in the future. Through our state-of-the-art manufacturing and technical infrastructure, Celularity can be an ideal development and manufacturing partner in the cellular medicine industry."


This was the initial reason for the partnership with Celularity. Turns out the placenta based cell material has the upper hand over what's been used today. So far allogeneic CAR-Ts are using healthy HUMAN donor cells, Celularity seems to be able produce even better " non-donor but still human cell material based" ones. Let's hope that IMU still got its foot in their door to secure capacities. Never a disadvantage to have 2 comps ( Cel and Kincell ) than just 1 producing those hard to get cells.

If those " verbally mortar throwing Masons" wouldn't come over telling us that all IMU got is crap, one could have hope for a better outcome one day.

GLTA